FDA Staff Scientists Disagree with Advisory Panel on Compounded Peptides

FDA staff scientists are in opposition to an advisory panel's recommendation to ease access to compounded peptides, creating uncertainty about the agency's future actions.

2 Aug, 12:49 — 2 Aug, 12:49

Post Share

Sources

Showing 1 of 1 sources

forbes22d ago

On Peptides, FDA Staff Scientists At Odds With Advisory Panel

Though FDA would normally follow a panel’s advice to move ahead with compounded peptides, it’s unclear how it will act, because FDA staff are opposed to easing access.

By Joshua P. Cohen, Senior Contributor

Read full article →

PERSPECTA

PERSPECTA

FDA Staff Scientists Disagree with Advisory Panel on Compounded Peptides

Sources

On Peptides, FDA Staff Scientists At Odds With Advisory Panel

Related Stories

Wall Street Futures Steady as Investors Await Nvidia Results and Fed Signals

Meta to Launch Hatch AI Agent Platform in Coming Weeks

Hanwha Aerospace Establishes US Unit for Global LNG Business Expansion

Big Food Industry Fights India's Proposed 'Red Flag' Labels on Sugary Drinks and Chips

PERSPECTA